Vis enkel innførsel

dc.contributor.authorNieder, Carsten
dc.contributor.authorDalhaug, Astrid
dc.contributor.authorHaukland, Ellinor Christin
dc.date.accessioned2022-03-30T10:54:26Z
dc.date.available2022-03-30T10:54:26Z
dc.date.issued2021-03
dc.description.abstractPurpose: The purpose of this study was to identify factors associated with the initiation or continuation of systemic treatment after brain irradiation. The outcome of interest was a utilization rate of at least 75%, given that active extracranial disease is common in patients with brain metastases. If left untreated, extracranial disease limits survival, regardless of successful local treatment of the brain metastases. In this context, systemic therapy has been shown to improve survival, e.g., after whole-brain radiotherapy. <p> <p>Patients and Methods: The study included 185 patients with active extracranial disease, 60% of whom received systemic therapy. <p> <p>Results: Survival from the start of brain irradiation was longest in patients who received additional immune checkpoint inhibitors, endocrine treatment, or anti-HER-2 drugs. After uni- and multivariate analyses, Eastern Cooperative Oncology Group performance status (PS) was selected as the first prediction criterion in the recursive partitioning analysis (RPA) decision tree analysis. RPA was successful for patients with PS 0–1, but patients with PS 2 had lower treatment utilization rates (maximum 60–70%, with a disease-dependent impact of age and LabBM score [blood test results]). The highest utilization rates were observed in (1) patients with PS 0 and (2) those with breast cancer, small-cell lung cancer, or lung adenocarcinoma with PS 1. <p> <p>Conclusions: These results inform the multidisciplinary discussion and treatment planning for the common scenario of simultaneous intra- and extracranial metastases.en_US
dc.descriptionThis is the accepted manuscript version of an article published by S. Karger AG in Oncology Research and Treatment. 2021;44(3):86-92, available at https://doi.org/10.1159/000513975.en_US
dc.identifier.citationNieder, Dalhaug, Haukland. Recursive partitioning analysis of systemic therapy after radiotherapy in patients with brain metastases. Oncology Research and Treatment. 2021;44(3):86-92en_US
dc.identifier.cristinIDFRIDAID 1909426
dc.identifier.doi10.1159/000513975
dc.identifier.issn2296-5270
dc.identifier.issn2296-5262
dc.identifier.urihttps://hdl.handle.net/10037/24648
dc.language.isoengen_US
dc.publisherKarger Publishersen_US
dc.relation.journalOncology Research and Treatment
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleRecursive partitioning analysis of systemic therapy after radiotherapy in patients with brain metastasesen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel